Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction

Journal of General Virology

Volumn 88, Issue 1, 2007, Pages 1-12

  Hanke, Tomáš ^a   McMichael, Andrew J ^a   Dorrell, Lucy ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BETA GALACTOSIDASE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; PLASMID DNA; PROTEIN P17; T LYMPHOCYTE ANTIGEN; VIRUS VECTOR;

AFRICA; CANARYPOX VIRUS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLADISTICS; CLINICAL TRIAL; DNA MODIFICATION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; EUROPE; EXPERIENCE; FOWLPOX VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; REVIEW; SKIN DEFECT; SKIN MANIFESTATION; T LYMPHOCYTE ACTIVATION; VACCINIA VIRUS; VIRUS RECOMBINANT;

AIDS VACCINES; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; PLASMIDS; T-LYMPHOCYTES; VACCINES, DNA; VACCINIA VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS 1; VACCINIA VIRUS ANKARA;

EID: 33846148643     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.82493-0     Document Type: Review

References (94)

1. AIDS Vaccine Evaluation Group 022 Protocol Team (2001). Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. J Infect Dis 183, 563-570.
2. Allen, T. M., Vogel, T. U., Fuller, D. H., Mothe, B. R., Steffen, S., Boyson, J. E., Shipley, T., Fuller, J., Hanke, T. & other authors (2000). Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol 164, 4968-4978.
3. Allen, T. M., Jing, P., Calore, B., Horton, H., O'Connor, D. H., Hanke, T., Piekarczyk, M., Ruddersdorf, R., Mothe, B. R. & other authors (2002). Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection. J Virol 76, 10507-10511.
4. Amara, R. R., Villinger, F., Altman, J. D., Lydy, S. L., O'Neil, S. P., Staprans, S. I., Montefiori, D. C., Xu, Y., Herndon, J. G. & other authors (2001). Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69-74.
5. Anonymous (2002). Use of AAV vectors in AIDS vaccine. Expert Rev Vaccines 1, 7.
6. Anonymous (2004). NIAID begins enrolling volunteers for Phase IIB study of Merck's vaccine. IAVI Rep 9, 16.
7. Anonymous (2005). Clinical trials yield promising results from two adenovirus-based vaccines. IAVI Rep 9, 24.
8. + T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 8, 379-385.
9. Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J. & Ahmed, R. (2006). Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682-687.
10. Barouch, D. H. & Nabel, G. J. (2005). Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 16, 149-156.
11. Barouch, D. H., Santra, S., Schmitz, J. E., Kuroda, M. J., Fu, T. M., Wagner, W., Bilska, M., Craiu, A., Zheng, X. X. & other authors (2000). Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486-492.
12. + T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J Immunol 168, 562-568.
13. Belshe, R. B., Gorse, G. J., Mulligan, M. J., Evans, T. G., Keefer, M. C., Excler, J. L., Duliege, A. M., Tartaglia, J., Cox, W. I. & other authors (1998). Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 12, 2407-2415.
14. Bins, A. D., Jorritsma, A., Wolkers, M. C., Hung, C. F., Wu, T. C., Schumacher, T. N. & Haanen, J. B. (2005). A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med 11, 899-904.
15. Cao, H., Kaleebu, P., Hom, D., Flores, J., Agrawal, D., Jones, N., Serwanga, J., Okello, M., Walker, C. & other authors (2003). immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. J Infect Dis 187, 887-895.
16. Casimiro, D. R., Bett A. J., Fu, T. M., Davies, M. E., Tang, A., Wilson, K. A., Chen, M., Long, R., McKelvey, T. & other authors (2004). Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol 78, 11434-11438.
17. Cebere, I., Dorrell, L., McShane, H., Simmons, A., McCormack, S., Schmidt, C., Smith, C., Brooks, M., Roberts, J. E. & other authors (2006). Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24, 417-425.
18. Chakrabarti, S., Brechling, K. & Moss, B. (1985). Vaccinia virus expression vector: coexpression of β-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol 5, 3403-3409.
19. Choi, M. J. & Maibach, H. I. (2003). Topical vaccination of DNA antigens: topical delivery of DNA antigens. Skin Pharmacol Appl Skin Physiol 16, 271-282.
20. Cosma, A., Nagaraj, R., Buhler, S., Hinkula, J., Busch, D. H., Sutter, G., Goebel, F. D. & Erfle, V. (2003). Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22, 21-29.
21. Czerkinsky, C. C., Tarkowski, A., Nilsson, L. A., Ouchterlony, O., Nygren, H. & Gretzer, C. (1984). Reverse enzyme-linked immunospot assay (RELISPOT) for the detection of cells secreting immunoreactive substances. J Immunol Methods 72, 489-496.
22. Davenport, M. P., Ribeiro, R. M., Chao, D. L. & Perelson, A. S. (2004). Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus. J Virol 78, 11340-11351.
23. Davis, N. L., West, A., Reap, E., Macdonald, G., Collier, M., Dryga, S., Maughan, M., Connell, M., Walker, C. & other authors (2002). Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life 53, 209-211.
24. Dorrell, L., Yang, H., Iversen, A. K., Conlon, C., Suttill, A., Lancaster, M., Dong, T., Cebere, I., Edwards, A. & other authors (2005). Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/ poly-epitope DNA vaccine. AIDS 19, 1321-1323.
25. Dorrell, L., Yang, H., Ondondo, B., Dong, T., di Gleria, K., Suttill, A., Conlon, C., Brown, D., Williams, P. & other authors (2006). Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. J Virol 80, 4705-4716.
26. Douek, D. C., Kwong, P. D. & Nabel, G. J. (2006). The rational design of an AIDS vaccine. Cell 124, 677-681.
27. + cytotoxic T lymphocyte population. Int Immunol 14, 31-37.
28. Estcourt, M. J., McMichael, A. J. & Hanke, T. (2004). DNA vaccines against human immunodeficiency virus type 1. Immunol Rev 199, 144-155.
29. + T cell help. Eur J Immunol 35, 3460-3467.
30. + T cell responses. Eur J Immunol 35, 2532-2540.
31. + cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 180, 290-298.
32. Farina, S. F., Gao, G. P., Xiang, Z. Q., Rux, J. J., Burnett, R. M., Alvira, M. R., Marsh, J., Ertl, H. C. & Wilson, J. M. (2001). Replication-defective vector based on a chimpanzee adenovirus. J Virol 75, 11603-11613.
33. Ferrantelli, F. & Ruprecht, R. M. (2002). Neutralizing antibodies against HIV - back in the major leagues? Curr Opin Immunol 14, 495-502.
34. Ferrari, G., Humphrey, W., McElrath, M. J., Excler, J. L., Duliege, A. M., Clements, M. L., Corey, L. C., Bolognesi, D. P. & Weinhold, K. J. (1997). Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A 94, 1396-1401.
35. Franchini, G., Gurunathan, S., Baglyos, L., Plotkin, S. & Tartaglia, J. (2004). Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev Vaccines 3, S75-S88.
36. Gilbert, S. C., Schneider, J., Plebanski, M., Hannan, C. M., Blanchard, T. J., Smith, G. L. & Hill, A. V. S. (1999). Ty virus-like particles, DNA vaccines and modified vaccinia virus Ankara; comparison and combinations. Biol Chem 380, 299-303.
37. Gilbert, S. C., Schneider, J., Hannan, C. M., Hu, J. T., Plebanski, M., Sinden, R. & Hill, A. V. (2002). Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 20, 1039-1045.
38. Global HIV/AIDS Vaccine Enterprise (2005). The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan. PLoS Med 2, e25.
39. + T-cell epitopes. J Virol 80, 4717-4728.
40. Gupta, K., Hudgens, M., Corey, L., McElrath, M. J., Weinhold, K., Montefiori, D. C., Gorse, G. J., Frey, S. E., Keefer, M. C. & other authors (2002). Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr 29, 254-261.
41. Gursel, M., Verthelyi, D., Gursel, I., Ishii, K. J. & Klinman, D. M. (2002). Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukoc Biol 71, 813-820.
42. Hanke, T. & McMichael, A. J. (2000). Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med 6, 951-955.
43. Hanke, T., Schneider, J., Gilbert, S. C., Hill, A. V. S. & McMichael, A. (1998a). DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine 16, 426-435.
44. Hanke, T., Blanchard, T. J., Schneider, J., Hannan, C. M., Becker, M., Gilbert, S. C., Hill, A. V. S., Smith, G. L. & McMichael, A. (1998b). Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16, 439-445.
45. Hanke, T., Samuel, R. V., Blanchard, T. J., Neumann, V. C., Allen, T. M., Boyson, J. E., Sharpe, A. S., Cook, N., Smith, G. L. & other authors (1999). Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 73, 7524-7532.
46. Hanke, T., McMichael, A. J., Samuel, R. V., Powell, L. A. J., McLoughlin, L., Crome, S. J. & Edlin, A. (2002). Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. Vaccine 21, 108-114.
47. Hanke, T., Barnfield, C., Wee, E. G.-T., Ågren, L., Samuel, R. V., Larke, N. & Liljeström, P. (2003). Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J Gen Virol 84, 361-368.
48. Hanke, T., McMichael, A. J., Dennis, M. J., Sharpe, S. A., Powell, L. A. J., McLoughlin, L. & Crome, S. J. (2005). Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. Vaccine 23, 1507-1514.
49. Harari, A., Zimmerli, S. C. & Pantaleo, G. (2004a). Cytomegalovirus (CMV)-specific cellular immune responses. Hum Immunol 65, 500-506.
50. Harari, A., Vallelian, F. & Pantaleo, G. (2004b). Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load. Eur J Immunol 34, 3525-3533.
51. Harrer, E., Bauerle, M., Ferstl, B., Chaplin, P., Petzold, B., Mateo, L., Handley, A., Tzatzaris, M., Vollmar, J. & other authors (2005). Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir Ther 10, 285-300.
52. Haynes, J. R., Fuller, D. H., McCabe, D., Swain, W. F. & Widera, G. (1996). Induction and characterization of humoral and cellular immune responses elicited via gene gun-mediated nucleic acid immunization. Adv Drug Delivery Rev 21, 3-18.
53. Hutchings, C. L., Gilbert, S. C., Hill, A. V. & Moore, A. C. (2005). Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-inediated immunity. J Immunol 175, 599-606.
54. Im, E.-J. & Hanke, T. (2004). MVA as a vector for vaccines against HIV-1. Expert Rev Vaccines 3, S89-S97.
55. + T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques. Eur J Immunol 36, 2574-2584.
56. Jin, X., Ramanathan, M., Jr, Barsoum, S., Deschenes, G. R., Ba, L., Binley, J., Schiller, D., Bauer, D. E., Chen, D. C. & other authors (2002). Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J Virol 76, 2206-2216.
57. Korber, B., Foley, B., Leitner, T., McCutchan, F., Hahn, B., Mellors, J. W., Myers, G. & Kuiken, C. (editors) (1997). Human retroviruses and AIDS 1997: a complilation and analysis of nucleic acid and amino acid sequences. Los Alamos, NM: Los Alamos National Laboratory.
58. Koshkina, N. V., Agoulnik, I. Y., Melton, S. L., Densmore, C. L. & Knight, V. (2003). Biodistribution and pharmacokinetics of aerosol and intravenously administered DNA-polyethyleneimine complexes: optimization of pulmonary delivery and retention. Mol Ther 8, 249-254.
59. + memory T cells. J Exp Med 186, 859-865.
60. Larke, N., Murphy, A., Wirblich, C., Teoh, D., Estcourt, M. J., McMichael, A. J., Roy, P. & Hanke, T. (2005). Induction of human immunodeficiency virus type 1-specific T cells by a bluetongue virus tubule-vectored vaccine prime-recombinant modified virus Ankara boost regimen. J Virol 79, 14822-14833.
61. Leifer, C. A., Verthelyi, D. & Klinman, D. M. (2003). Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides. J Immunother 26, 313-319.
62. Levy, Y., Gahery-Segard, H., Durier, C., Lascaux, A. S., Goujard, C., Meiffredy, V., Rouzioux, C., El Habib, R., Beumont-Mauviel, M. & other authors (2005). Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 19, 279-286.
63. Levy, Y., Durier, C., Lascaux, A. S., Meiffredy, V., Gahery-Segard, H., Goujard, C., Rouzioux, C., Resch, M., Guillet, J. G. & other authors (2006). Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 20, 405-413.
64. Maino, V. C. & Picker, L. J. (1998). Identification of functional subsets by flow cytometry: intracellular detection of cytokine expression. Cytometry 34, 207-215.
65. McShane, H., Pathan, A. A., Sander, C. R., Keating, S. M., Gilbert, S. C., Huygen, K., Fletcher, H. A. & Hill, A. V. (2004). Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10, 1240-1244.
66. Moorthy, V. S., Pinder, M., Reece, W. H., Watkins, K., Atabani, S., Hannan, C., Bojang, K., McAdam, K. P., Schneider, J. & other authors (2003). Safety and immunogenicity of DNA/modified vaccinia virus Ankara malaria vaccination in African adults. J Infect Dis 188, 1239-1244.
67. Mosteller, R. D. (1987). Simplified calculation of body-surface area. N Engl J Med 317, 1098.
68. Musey, L., Ding, Y., Elizaga, M., Ha, R., Celum, C. & McElrath, M. J. (2003). HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T cell immunity in HIV-1-uninfected individuals. J Imumnol 171, 1094-1101.
69. Mwau, M., McMichael, A. J. & Hanke, T. (2002). Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines. AIDS Res Hum Retroviruses 18, 611-618.
70. Mwau, M., Cebere, I., Sutton, J., Chikoti, P., Winstone, N., Wee, E. G.-T., Beattie, T., Chen, Y.-H., Dorrel, L. & other authors (2004). A human immunodeficiency virus 1 (HIV- 1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 85, 911-919.
71. Nkolola, J. P., Wee, E. G.-T., Im, E.-J., Jewell, C. P., Chen, N., Xu, X.-N., McMichael, A. J. & Hanke, T. (2004). Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa. Gene Ther 11, 1068-1080.
72. Nordström, E. K. L., Forsell, M. N. E., Barnfield, C., Bonin, E., Hanke, T., Sundström, M., Karlsson, G. B. & Liljeström, P. (2005). Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1. J Gen Virol 86, 349-354.
73. + T cell responses. Eur J Immunol 36, 2585-2594.
74. Raviprakash, K., Ewing, D., Simmons, M., Porter, K. R., Jones, T. R., Hayes, C. G., Stout, R. & Murphy, G. S. (2003). Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys. Virology 315, 345-352.
75. Robbins, G. K., Addo, M. M., Troung, H., Rathod, A., Habeeb, K., Davis, B., Heller, H., Basgoz, N., Walker, B. D. & Rosenberg, E. S. (2003). Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS 17, 1121-1126.
76. Roberts, D. M., Nanda, A., Havenga, M. J., Abbink, P., Lynch, D. M., Ewald, B. A., Liu, J., Thorner, A. R., Swanson, P. E. & other authors (2006). Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441, 239-243.
77. + T cell responses associated with control of viremia. Science 278, 1447-1450.
78. Rowland-Jones, S. L., Pinheiro, S., Kaul, R., Hansasuta, P., Gillespie, G., Dong, T., Plummer, F. A., Bwayo, J. B., Fidler, S. & other authors (2001). How important is the 'quality' of the cytotoxic T lymphocyte (CTL) response in protection against HIV infection? Immunol Lett 79, 15-20.
79. Santra, S., Barouch, D. H., Korioth-Schmitz, B., Lord, C. I., Krivulka, G. R., Yu, F., Beddall, M. H., Gorgone, D. A., Lifton, M. A. & other authors (2004). Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proc Natl Acad Sci U S A 101, 11088-11093.
80. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4, 397-402.
81. Schulz, O., Diebold, S. S., Chen, M., Naslund, T. I., Nolte, M. A., Alexopoulou, L., Azuma, Y. T., Flavell, R. A., Liljeström, P. & other authors (2005). Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433, 887-892.
82. Slyker, J. A., Lohman, B. L., Mbori-Ngacha, D. A., Reilly, M., Wee, E. G., Dong, T., McMichael, A. J., Rowland-Jones, S. L., Hanke, T. & John-Stewart, G. (2005). Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants. Vaccine 23, 4711-4719.
83. + T cells after acute infection. Nat Immunol 5, 927-933.
84. Tubiana, R., Carcelain, G., Vray, M., Gourlain, K., Dalban, C., Chermak, A., Rabian, C., Vittecoq, D., Simon, A. & other authors (2005). Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). Vaccine 23, 4292-4301.
85. UNAIDS (2004). AIDS Epidemic Update: December 2004. Geneva: UNAIDS/WHO. http://www.who.int/hiv/pub/epidemiology/epiupdate/en/index.html
86. van Baalen, C. A., Guillon, C., van Baalen, M., Verschuren, E. J., Boers, P. H., Osterhaus, A. D. & Gruters, R. A. (2002). Impact of antigen expression kinetics on the effectiveness of HIV-specific cytotoxic T lymphocytes. Eur J Immunol 32, 2644-2652.
87. Vordermeier, H. M., Rhodes, S. G., Dean, G., Goonetilleke, N., Huygen, K., Hill, A. V., Hewinson, R. G. & Gilbert, S. C. (2004). Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guerin. Immunology 112, 461-470.
88. Vuola, J. M., Keating, S., Webster, D. P., Berthoud, T., Dunachie, S., Gilbert, S. C. & Hill, A. V. (2005). Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 174, 449-455.
89. Webster, D. P., Dunachie, S., Vuola, J. M., Berthoud, T., Keating, S., Laidlaw, S. M., McConkey, S. J., Poulton, I., Andrews, L. & other authors (2005). Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A 102, 4836-4841.
90. Wee, E. G.-T., Patel, S., McMichael, A. J. & Hanke, T. (2002). A DNA/ MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. J Gen Virol 83, 75-80.
91. Williams, S. G., Cranenburgh, R. M., Weiss, A. M. E., Wrighton, C. J., Sherratt, D. J. & Hanak, J. A. J. (1998). Repressor titration: a novel system for selection and stable maintenance of recombinant plasmids. Nucleic Acids Res 26, 2120-2124.
92. Williams, A., Goonetilleke, N. P., McShane, H., Clark, S. O., Hatch, G., Gilbert, S. C. & Hill, A. V. (2005). Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. Infect Immun 73, 3814-3816.
93. Zhang, D., Shankar, P., Xu, Z., Harnisch, B., Chen, G., Lange, C., Lee, S. J., Valdez, H., Lederman, M. M. & Lieberman, J. (2003a). Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood 101, 226-235.
94. Zhang, L., Widera, G., Bleecher, S., Zaharoff, D. A., Mossop, B. & Rabussay, D. (2003b). Accelerated immune response to DNA vaccines. DNA Cell Biol 22, 815-822.